Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

332 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Durable immunity to EBV after rituximab and third-party LMP-specific T cells: a Children's Oncology Group study.
Wistinghausen B, Toner K, Barkauskas DA, Jerkins LP, Kinoshita H, Chansky P, Pezzella G, Saguilig L, Hayashi RJ, Abhyankar H, Scull B, Karri V, Tanna J, Hanley P, Hermiston ML, Allen CE, Bollard CM. Wistinghausen B, et al. Among authors: hanley p. Blood Adv. 2024 Mar 12;8(5):1116-1127. doi: 10.1182/bloodadvances.2023010832. Blood Adv. 2024. PMID: 38163318 Free PMC article.
Outcomes following posttransplant virus-specific T-cell therapy in patients with sickle cell disease.
Kinoshita H, Mandava M, Jensen-Wachspress M, Lang H, Joy E, Tanna J, McCann CD, O'Brien S, Burnett S, Shibli A, Hoq F, Bhatia M, Hanley PJ, Dávila Saldaña B, Mahadeo KM, Bollard CM, Keller MD, Abraham A. Kinoshita H, et al. Blood Adv. 2023 May 23;7(10):2105-2116. doi: 10.1182/bloodadvances.2022008219. Blood Adv. 2023. PMID: 36516084 Free PMC article.
Third-Party and Patient-Specific Donor-Derived Virus-Specific T Cells Demonstrate Similar Efficacy and Safety for Management of Viral Infections after Hematopoietic Stem Cell Transplantation in Children and Young Adults.
Galletta TJ, Lane A, Lutzko C, Leemhuis T, Cancelas JA, Khoury R, Wang YM, Hanley PJ, Keller MD, Bollard CM, Davies SM, Grimley MS, Rubinstein JD. Galletta TJ, et al. Transplant Cell Ther. 2023 May;29(5):305-310. doi: 10.1016/j.jtct.2023.01.027. Epub 2023 Feb 3. Transplant Cell Ther. 2023. PMID: 36736781 Free article.
The Effects of Human Immunodeficiency Virus Type 1 (HIV-1) Antigen-Expanded Specific T-Cell Therapy and Vorinostat on Persistent HIV-1 Infection in People With HIV on Antiretroviral Therapy.
Gay CL, Hanley PJ, Falcinelli SD, Kuruc JD, Pedersen SM, Kirchherr J, Raines SLM, Motta CM, Lazarski C, Chansky P, Tanna J, Shibli A, Datar A, McCann CD, Sili U, Ke R, Eron JJ, Archin N, Goonetilleke N, Bollard CM, Margolis DM. Gay CL, et al. Among authors: hanley pj. J Infect Dis. 2024 Mar 14;229(3):743-752. doi: 10.1093/infdis/jiad423. J Infect Dis. 2024. PMID: 38349333
Emerging frontiers in immuno- and gene therapy for cancer.
Gustafson MP, Ligon JA, Bersenev A, McCann CD, Shah NN, Hanley PJ. Gustafson MP, et al. Among authors: hanley pj. Cytotherapy. 2023 Jan;25(1):20-32. doi: 10.1016/j.jcyt.2022.10.002. Epub 2022 Oct 22. Cytotherapy. 2023. PMID: 36280438 Free PMC article. Review.
Third-party virus specific T cells for the treatment of double stranded DNA viral reactivation and PTLD after solid organ transplant.
Khoury R, Grimley MS, Nelson AS, Leemhuis T, Cancelas JA, Cook E, Wang Y, Heyenbruch D, Bollard CM, Keller MD, Hanley PJ, Lutzko C, Pham G, Davies SM, Rubinstein JD. Khoury R, et al. Among authors: hanley pj. Am J Transplant. 2024 Apr 19:S1600-6135(24)00280-6. doi: 10.1016/j.ajt.2024.04.009. Online ahead of print. Am J Transplant. 2024. PMID: 38643944
Antiviral cellular therapy for enhancing T-cell reconstitution before or after hematopoietic stem cell transplantation (ACES): a two-arm, open label phase II interventional trial of pediatric patients with risk factor assessment.
Keller MD, Hanley PJ, Chi YY, Aguayo-Hiraldo P, Dvorak CC, Verneris MR, Kohn DB, Pai SY, Dávila Saldaña BJ, Hanisch B, Quigg TC, Adams RH, Dahlberg A, Chandrakasan S, Hasan H, Malvar J, Jensen-Wachspress MA, Lazarski CA, Sani G, Idso JM, Lang H, Chansky P, McCann CD, Tanna J, Abraham AA, Webb JL, Shibli A, Keating AK, Satwani P, Muranski P, Hall E, Eckrich MJ, Shereck E, Miller H, Mamcarz E, Agarwal R, De Oliveira SN, Vander Lugt MT, Ebens CL, Aquino VM, Bednarski JJ, Chu J, Parikh S, Whangbo J, Lionakis M, Zambidis ET, Gourdine E, Bollard CM, Pulsipher MA. Keller MD, et al. Among authors: hanley pj. Nat Commun. 2024 Apr 18;15(1):3258. doi: 10.1038/s41467-024-47057-2. Nat Commun. 2024. PMID: 38637498 Free PMC article. Clinical Trial.
Accelerating the development of genetically engineered cellular therapies: a framework for extrapolating data across related products.
Stewart MD, Kalos M, Coutinho V, Better M, Jazayeri J, Yohrling J, Jadlowsky J, Fuchs M, Gidwani S, Goessl C, Hanley PJ, Healy J, Liu W, McKelvey BA, Pearce L, Pilon-Thomas S, Andrews HS, Veldman M, Vong J, Weinbach SP, Allen JD. Stewart MD, et al. Among authors: hanley pj. Cytotherapy. 2024 Mar 16:S1465-3249(24)00097-5. doi: 10.1016/j.jcyt.2024.03.009. Online ahead of print. Cytotherapy. 2024. PMID: 38583170 Free article.
Secondary bone marrow graft loss after third-party virus-specific T cell infusion: Case report of a rare complication.
Keller MD, Schattgen SA, Chandrakasan S, Allen EK, Jensen-Wachspress MA, Lazarski CA, Qayed M, Lang H, Hanley PJ, Tanna J, Pai SY, Parikh S, Berger SI, Gottschalk S, Pulsipher MA, Thomas PG, Bollard CM. Keller MD, et al. Among authors: hanley pj. Nat Commun. 2024 Mar 29;15(1):2749. doi: 10.1038/s41467-024-47056-3. Nat Commun. 2024. PMID: 38553461 Free PMC article.
332 results